Xintela AB (SE:XINT)
:XINT
Want to see SE:XINT full AI Analyst Report?
XINT Stock Chart & Stats
kr0.28
-kr0.02(-4.02%)
At close: 4:00 PM EST
kr0.28
-kr0.02(-4.02%)
Day’s Range― - ―
52-Week Rangekr0.21 - kr0.53
Previous CloseN/A
Volume22.80K
Average Volume (3M)554.92K
Market Cap
kr201.54M
Enterprise Valuekr144.19M
Total Cash (Recent Filing)kr23.21M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.78
Next Earnings
May 22, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding861,266,850
10 Day Avg. Volume503,836
30 Day Avg. Volume554,918
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)-37.15
Price to Sales (P/S)85.84
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary ITGA10 PlatformXintela’s patented ITGA10 platform is a durable competitive asset across regenerative medicine and oncology. A platform enables reuse of R&D across indications, creates multiple program shots on goal, and supports long-term licensing or co-development revenue streams if clinical proof points are achieved.
Low Leverage (zero Debt)Zero reported debt materially reduces refinancing and interest-pressure risk for a clinical-stage biotech. Low leverage preserves strategic flexibility to pursue partnerships or milestone-focused development, and allows capital-raise options without immediate debt servicing constraints over the medium term.
Partnering / Out-licensing ModelA partnering and out-licensing commercialization model aligns with the platform strategy and can de-risk capital intensity. By focusing on milestones, upfronts and royalties, Xintela can access partner capabilities for late-stage development and commercialization while limiting required internal commercial investment.
Bears Say
Sustained Operating Cash BurnOperating cash flow has been structurally and heavily negative across multiple years, indicating persistent cash consumption. This ongoing burn increases dependence on external financing or partner milestone payments, raises dilution risk, and constrains the company’s ability to advance programs independently over the medium term.
Negative Shareholders' EquityNegative shareholders’ equity signals accumulated losses and weak balance-sheet resilience. This condition can limit financing alternatives, reduce bargaining power with partners, and make the firm more vulnerable to setbacks, requiring timely external capital or strategic transactions to sustain operations.
Small, Volatile Revenue BaseRevenue remains small and unstable, with a meaningful decline in 2025. Such volatility and limited scale mean revenues cannot absorb fixed R&D and SG&A, keeping profitability out of reach and increasing reliance on milestone, grant, or financing events rather than sustainable product cash flows.
Xintela AB News
XINT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was kr0.21 and its highest was kr0.53 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is kr201.54M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is May 22, 2026 which is in 21 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on Feb 27, 2026. The company reported -kr0.02 earnings per share for the quarter, missing the consensus estimate of -kr0.01 by -kr0.01.
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is -0.01.
How many shares outstanding does Xintela AB have?
Xintela AB has 861,266,850 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of -kr0.02 in its last earnings report, missing expectations of -kr0.01. Following the earnings report the stock price went up 1.838%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in SE:XINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.
Technical Analysis
Isofol Medical AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―